Latest Options News

Bowen Coking Coal has announced it will remain suspended on the ASX as it reassesses its operational plans and explores financing options amid challenging market conditions.

Canyon Resources has secured a significant credit facility and advanced key contracts, setting the stage for production and first bauxite shipments from its Minim Martap project in early 2026.

Vanguard Investments Australia has announced estimated distribution amounts for over 30 ETFs, with payments scheduled for mid-July 2025. This detailed timetable offers investors clarity on income expectations and reinvestment options.

Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.

Iron Road Ltd has entered a staged Farm-In and Joint Venture agreement with Red Tiger Resources to explore the promising EL6580 tenement in South Australia, targeting heavy mineral sands and other critical minerals. The deal includes a phased investment approach with potential to increase Iron Road’s stake to 70%.

Magellan Asset Management announces a 7.33 cents per unit final distribution for the Airlie Australian Share Fund – Active ETF for the six months ended June 30, 2025, alongside key dates for investors to note.

Magellan Asset Management announces a 16.25 cents per unit final distribution for its Global Fund Active ETF for the six months ending June 2025, with key dates set for early July.

Wide Open Agriculture has achieved a breakthrough in lupin protein production, slashing energy consumption by up to 80% and halving processing time in a recent commercial-scale trial. These efficiency gains pave the way for more cost-effective, scalable manufacturing.

Firebrick Pharma has raised $0.2 million in a placement well below its $1.6 million target, prompting a review of its expansion and product development plans for Nasodine.

A critical system error by Computershare led to the exclusion of key proxy votes in PointsBet's shareholder scheme meeting, causing the acquisition resolution by MIXI to fail.

Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.

Singular Health Group has completed a $7.85 million capital raising through a new share issue, alongside additional funds from option exercises, strengthening its financial position for growth in medical imaging technology.